CCM
ELEV

CAAS Capital Management’s Elevation Oncology ELEV Stock Holding History

CAAS Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,678
Closed -$82K – 741
2021
Q4 		$82K Sell
13,678
-46,322
-77% -$320K ﹤0.01% 725
2021
Q3 		$467K Hold
60,000
– – 0.01% 637
2021
Q2 		$814K Buy
+60,000
New +$742K 0.01% 637

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

CAAS Capital Management's ELEV Position: Q1 2022 in Review

CAAS Capital Management sold out of Elevation Oncology (ELEV) in Q1 2022, closing a stake of 13,678 shares — an estimated $82K sold.

CAAS Capital Management first reported a position in ELEV in Q2 2021 and held it in 3 quarters. The position peaked at $814K in Q2 2021. 31 funds tracked by Wall St. Rank hold ELEV as of Q1 2022.

  • CAAS Capital Management reported no remaining Elevation Oncology position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 13,678 Elevation Oncology shares in Q1 2022, an estimated $82K.
  • CAAS Capital Management first reported a position in Elevation Oncology in Q2 2021 and held it in 3 quarters.
  • CAAS Capital Management's Elevation Oncology position peaked at $814K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.